Aerosol Delivery of CPZEN-45 for Treatment of Nontuberculous Mycobacterial (NTMs) Infections
Abstract
This DOD Therapeutic Development Award is focused on a new antibiotic, CPZEN-45, discovered by our team for treatment of non-tuberculous mycobacterial infections (NTM) in patients with chronic obstructive pulmonary disease (COPD). We have two major objectives: Objective 1-To optimize fermentation and scale-up of manufacturing processes for high yield of CPZEN-45, including spray dried CPZEN-45. Objective 2- To further define and characterize in vitro efficacy of CPZEN-45 against additional species of NTMs recently isolated from VA patients with COPD. Specifically, our objective is to develop an efficacious regimen for COPD patients by screening multiple CPZEN-45 combinations with standard NTM compounds in human THP-1 cells using a checkerboard assay. Synergy measurement by checkerboard analysis will be used to determine the impact on potency of the combination of antibiotics in comparison to their individual activities. The optimized synergistic regimens will then be tested in COPD mouse and guinea pig efficacy models.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2021
- Accession Number
- AD1162367
Entities
People
- Darrick Carter
- Gail Cassell